NEW YORK (TheStreet) -- CHANGE IN RATINGS:Apple ( AAPL) was downgraded at Pacific Crest to sector perform. High end of the market appears saturated, Pacific Crest said. Estimates also cut. Cascade Bancorp ( CACB) was upgraded to hold at TheStreet Ratings. Dell ( DELL) was downgraded at Argus from buy to hold. Stock has already made a big run on takeover speculation, Argus said. Ironwood Pharmaceutical ( IRWD) was downgraded at UBS to sell from neutral. $11.50 price target. Expectations too high, UBS said. Ironwood Pharmaceuticals was downgraded to sell at TheStreet Ratings. Intermune ( ITMN) was upgraded at UBS to buy from neutral. $15 price target. Short-term hurdles removed, UBS said. Kellogg ( K) was downgraded at Credit Suisse from neutral to underperform. Valuation call, based on a $55 price target, Credit Suisse said. Mead Johnson ( MJN) was downgraded at Credit Suisse from outperform to neutral. Estimates were also cut, given lower expected sales growth, Credit Suisse said. $76 price target. Sealed Air ( SEE) was upgraded at Citigroup to buy from neutral. $22 price target. Operational improvement under an aggressive new leadership, Citi said. Valmont ( VMI) was initiated with a neutral rating at Wedbush. $160 price target. Valuation call, as the stock is up 47% over the past year, Wedbush said. Whiting Petroleum ( WLL) was upgraded at Sterne Agee to buy. $62 price target. Company is looking to raise cash for acquisitions, to pay down debt or to offer a dividend, Sterne Agee said.
STOCK COMMENTS / EPS CHANGESApple ( AAPL) estimates, target cut at BofA/Merrill. AAPL estimates were reduced through 2015, Bank of America/Merrill Lynch said. Company is facing increased smartphone competition. Buy rating and new $630 price target. Atmel ( AMTL) estimates, target raised at Canaccord. Shares of ATML now seen reaching $8, according to Canaccord Genuity. Estimates also increased, given higher netbook touch penetration. Buy rating. Boeing ( BA) cut from Conviction Buy List at Goldman. 787 risks continue to mount. $90 price target. Bristol Myers Squibb ( BMY) numbers raised at Jefferies. Shares of BMY now seen reaching $39, Jefferies said. Estimates also raised on big year for clinical trial results. Buy rating. Eaton Vance ( EV) numbers increased at BMO. EV estimates were raised through 2014, BMO Capital said. Company is attracting more assets. Market Perform rating and new $32 price target. Express ( EXPR) estimates, target upped at BMO. EXPR estimates were boosted through 2013, BMO Capital said. Company saw higher demand throughout the holidays. Outperform rating and new $19 price target. Facebook ( FB) target boosted at BofA/Merrill to $35. New advertising formats and mobile traction should continue to drive revenue acceleration. Buy rating. Google ( GOOG) estimates lowered at Canaccord through 2014, Canaccord Genuity said. Expect lower Nexus margins and higher acquisition costs. Buy rating and $810 price target. Lululemon ( LULU) estimates, target cut at Credit Suisse. Shares of LULU now seen reaching $79, according to Credit Suisse. Estimates also reduced, given moderating comp sales. Neutral rating. Marathon Oil ( MRO) numbers raised at Oppenheimer. Shares of MRO now seen reaching $40, Oppenhiemer said. Estimates also raised on improved outlook. Outperform rating. Pfizer ( PFE) numbers raised at Jefferies. Shares of PFE now seen reaching $31, Jefferies said. Estimates also raised on big year for clinical results. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.